Abstract: A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.
Type:
Grant
Filed:
August 9, 2000
Date of Patent:
December 17, 2002
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
John M. Pezzuto, Tapas K. DasGupta, Darrick S. H. L. Kim
Abstract: A method for therapeutic or prophylactic control of Acquired Immunodeficiency Syndrome (AIDS) in which an effective dose of phosphonoformic acid or a therapeutically-acceptable salt thereof is administered to a patent.
Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to isoquinoline derivatives.
Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
Type:
Grant
Filed:
January 10, 2001
Date of Patent:
November 26, 2002
Assignee:
Eli Lilly and Company
Inventors:
Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
Abstract: The present invention relates to a method of inhibiting the activity of the HIV virus in a human comprising administering to the human an effective dose of phosphonoformic acid or a therapeutically effective salt thereof.
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Type:
Grant
Filed:
April 7, 2000
Date of Patent:
October 22, 2002
Assignee:
The Children's Medical Center Corporation
Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.
Abstract: This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone.
Abstract: Use of compounds of the formula I
for preparing a medicament for protecting DNA in the initial phase and/or the promoting phase of carcinogenesis and for preventing oxidative stress in patients with diseases related to free radicals are described.
Type:
Grant
Filed:
March 19, 2001
Date of Patent:
October 15, 2002
Inventors:
Jan Bergman, Lennart Möller, Hans Vallberg
Abstract: This invention is concerned with the clinical investigation of the therapeutic effects of garlic extracts containing allicin, diallyl disulfide, and diallyl trisulfide. The intake of garlic or therapeutically active substances such as allicin from garlic, induces immunostimulation and these active substances possess strong antitumor effects including the apoptosis of tumors, including the programmed cell death of human prostatic and bladder tumor cells. This invention claims that garlic and/or garlic extracts possess very effective therapeutic substances useful not only to treat human prostate and bladder cancers to extend life span of patients, but also to suppress or prevent bladder and prostate gland cancers.
Type:
Grant
Filed:
July 5, 2000
Date of Patent:
October 15, 2002
Assignee:
Korea Chungang Educational Foundation
Inventors:
Jun Cheon, Jejong Kim, Jungku Lee, Hankyeum Kim, Doogun Moon
Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
Type:
Grant
Filed:
September 26, 2000
Date of Patent:
October 8, 2002
Assignee:
The Procter & Gamble Company
Inventors:
James Berger Camden, James C. Quada, Jr., Joseph K. Agyin
Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
Type:
Grant
Filed:
February 4, 2000
Date of Patent:
October 8, 2002
Assignee:
Galderma Research & Development S.N.C.
Inventors:
Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.
Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.
Type:
Grant
Filed:
March 30, 1999
Date of Patent:
September 17, 2002
Assignee:
Hormos Nutraceutical Oy Ltd.
Inventors:
Markku Ahotupa, Chester Eckerman, Lauri Kangas, Sari Mäkelä, Niina Saarinen, Risto Santti, Anni Wärri
Abstract: Lipoic acid and/or its water soluble salt is used to treat cancer, alone or in combination with ascorbic acid (vitamin C). Alone or in combination, it was shown to be effective on in vitro tumors and mouse tumors. The agents can be administered safely, and have been used effectively in case studies.
Type:
Grant
Filed:
July 23, 1999
Date of Patent:
September 10, 2002
Assignee:
The Center for the Improvement of Human Functioning, INTL.,
Inc.
Abstract: The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.
Type:
Grant
Filed:
May 8, 2001
Date of Patent:
September 10, 2002
Assignee:
University of Massachusetts
Inventors:
Sumner H. Burstein, Lawrence D. Recht, Robert B. Zurier
Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
Type:
Grant
Filed:
January 7, 2000
Date of Patent:
September 3, 2002
Assignee:
New Life Pharmaceuticals Inc.
Inventors:
Gustavo C. Rodriguez, Regina Salas Whitaker
Abstract: A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.
Abstract: Pharmaceutical compositions having enhanced antitumor activity or reduced side effects. The compositions include both (A) a known active substance having antitumor effect or a pharmaceutically suitable salt thereof and (B) an effective amount of a hydroximic acid derivative of formula (I)
or a therapeutically useful acid addition salt thereof. Also disclosed are methods for reducing side effects in patients requiring treatment for tumors.